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Regulation of the Expression of Epidermal Growth Factor Receptor
mRNA with Thyroid Hormone L-3,5,3'-Triiodothyronine in Rat Hepatoma
Cells
Yukio Satoh and Takeshi Sairenji
Department of Biosignaling, Faculty of Medicine, Tottori University, Yonago 683, Japan
The expression of epidermal growth factor (EGF) receptor mRNA was examined using
thyroid hormone L-3,5,3'-triiodothyronine (T3) by Northern blot analysis in rat
hepatoma cells.  The expression of full-length, but not truncated receptor mRNA was
enhanced and destabilized with T3.  These results suggest that T3 induces not only the
expression of full-length EGF receptor mRNA but also accelerates their rate of turnover.
The 3' terminal region of full-length EGF receptor mRNA may have a role in the
destabilization of EGF receptor mRNA by T3, because truncated EGF receptor mRNA
lacks only the 3' terminal region of full-length EGF receptor mRNA.
Key words:  EGF receptor; EGF receptor mRNA; mRNA stability; regulation of gene expression;
thyroid hormone
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triiodothyronine
The epidermal growth factor (EGF) receptor
mediates cell proliferation by EGF or trans-
forming growth factor α (Carpenter and Cohen,
1990).  Normal rat liver cells express full-length
and truncated EGF receptor messenger RNAs
(mRNAs) (Petch et al., 1990; Satoh et al., 1996,
1997).  Full-length EGF receptor mRNA en-
codes a transmembrane EGF receptor tyrosine
kinase, c-ErbB1.  Truncated EGF receptor
mRNA encodes a secreted EGF-binding protein
with a yet unknown physiological function
(Ullrich et al., 1984).  Regulation of the gene
expression of EGF receptors has not been well
understood.  Full-length and truncated EGF
receptor mRNAs initiate from the same 5' site
(Ishii et al., 1985) and are subsequently
processed into different forms by alternative
splicing (Petch et al., 1990).  Expression of
EGF receptors has been reported to be regulated
by thyroid hormone (Mukku, 1984; Vonderhaar
et al., 1986).  Thyroid hormone is a ligand of c-
ErbA, a member of the steroid/nuclear receptor
superfamily of ligand-regulated transcription
factors (Tsai and O’Malley, 1994).  However,
the EGF receptor promoter has not been report-
ed to contain the thyroid hormone-responsive
element, while it was recently reported to have
putative estrogen-responsive elements (Yarden
et al., 1996).  Thyroid hormone was also
reported to decrease the length of the poly(A)
tract of mRNA (Krane et al., 1991; Murphy et
al., 1992).
Here we studied the effect of a thyroid
hormone, L-3,5,3'-triiodothyronine (T3) on the
expressions of full-length and truncated EGF
receptor mRNAs in rat hepatoma cells.  We
found that full-length EGF receptor mRNA was




AH66 cells provided by Dr. K. Sato (Depart-
ment of Molecular Biology, Tottori University,
Yonago, Japan) were cultured in Dulbecco’s
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Modified Eagle’s Medium (Nissui Pharma-
ceutical Co. Ltd., Tokyo, Japan) with 10% new-
born calf serum (NCS; Filtron Ltd., Brooklyn,
Australia) at 37˚C in a humidified atmosphere
containing 5% CO2.
Treatment of cells with thyroid hormone
and 5,6-dichlororibofuranosylbenzimida-
zole (DRB)
Cells were inoculated at 5 × 105 cells/dish in 9
cm plastic dishes and cultured for 48 h.  The
cells were rinsed with serum-free medium and
cultured in the medium containing 3% dextran-
charcoal-treated NCS (DCC-NCS), which was
free of thyroid hormone, with or without 100
nM T3 (Nacalai Tesque, Inc., Kyoto, Japan) for
3 h.  For the measurement of stability of mRNA,
the culture medium was changed to the fresh
Fig. 1.  Effect of T3 on the expression of EGF receptor mRNAs in AH66 cells.  Cells were cultured
with (+T3) or without (–T3) 100 nM T3 for 3 h at 37˚C and were then treated with DRB and cultured
with or without T3 for indicated times.  RNA was extracted from the cells and was analyzed by
Northern blot.  A: Upper panel;  EGF receptor mRNA proved with the cDNA probe.  Sizes of the
mRNA are shown on the left side.  Lower panel; RNA (20 µg/lane) stained by ethidium bromide.
B: The levels of 10 and 2.7 kb EGF receptor mRNAs were quantitated and shown as a function of
time after the addition of DRB.  The background level (13.9 cpm) of the same area was subtracted.
Data were reproduced three times by repeated experiments.
medium containing 65 µM DRB (Harrold et al.,
1991; Sigma-Aldrich Japan K.K., Tokyo) and
3% DCC-NCS with or without 100 nM T3 and
cells were cultured for an indicated time.
Northern blot analysis
RNA was extracted from the cells by the acid
guanidinium thiocyanate-phenol-chloroform
method (Chomozynski and Sacchi, 1987) and
was analyzed by Northern blot analysis as
described previously (Satoh et al., 1997).  The
RNA was denatured, electrophoresed and trans-
ferred to a nylon membrane.  The membrane
was hybridized with the probe, washed and ex-
posed to an X-ray film.  The rat EGF receptor
cDNA encoding extracellular domain (Petch et
al., 1990) was provided by Dr. H. Shelton Earp
(University of North Carolina at Chapel Hill,
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North Carolina, USA) and used as the 32P-
labeled probe for EGF receptor mRNA.  The
EGF receptor mRNA level was quantitated by
an AMBIS 4000 image analyzer (Japan
Medical Dynamic Marketing Inc., Tokyo,
Japan).
Results
AH66 cells were cultured in the presence or
absence of T3 for 3 h, and then RNA synthesis
was stopped by the addition of DRB and
cultured in the presence or absence of T3.  After
the incubation, total cellular RNA was prepared
at various time points and was subjected to
Northern blot analysis with the EGF receptor
cDNA probe (Fig. 1A).  Ten, 7 and 5 kb full-
length and 2.7 kb truncated EGF receptor
mRNAs were detected in the cells as previously
described (Satoh et al., 1996, 1997).  The bands
of the full-length EGF receptor mRNA were
much darker in the presence of T3 (lane 1) than
in the absence of T3 (lane 6).  The mRNA levels
of the 10 and 2.7 kb were quantitated by the
image analyzer (Fig. 1B).  The level of 10 kb
mRNA with T3 treatment was 10-fold higher
than T3-untreated cells at 0 h.  However, the
level reduced rapidly to the level of T3-
untreated cells by 2 h after the addition of DRB.
On the other hand, in the absence of T3, the low
level of 10 kb mRNA was detected and did not
change significantly up to 5 h after the addition
of DRB.  In contrast, the level of 2.7 kb mRNA
was not affected by the T3 treatment as shown at
0 h and did not change for 5 h in the presence of
DRB.  The effect of T3 on the levels of 7 and 5
kb mRNAs was similar to those of 10 kb mRNA
(data not shown).  These results indicate that T3
induced the expression of the mRNA of the full-
length EGF receptor and had accelerated turn-
over.  However it did not have such an effect on
the truncated receptor mRNA.
Discussion
It has been reported that thyroid hormone
upregulates EGF receptor protein in cells of rat
liver (Mukku, 1984) and mouse mammary
glands (Vonderhaar et al., 1986).  We found
that the level of full-length EGF receptor
mRNA was upregulated with T3 in rat hepa-
toma cell line, AH66 cells.  This is consistent
with the following reports: the enhancement of
EGF binding to the membranes of liver and
mammary glands of euthyroid animals as
opposed to hypothyroid controls (Mukku, 1984;
Vonderhaar et al., 1986), the enhancement of
the transcription of EGF receptor in T3-treated
human mammary cells (Fernandez-Pol et al.,
1989) and the stimulation of T3 on the level of
5.6 kb EGF receptor mRNA in human epi-
dermoid cells (Kesavan et al., 1991).  The
higher level of 10 kb mRNA in the T3-treated
cells may suggest that the expression of full-
length EGF receptor mRNA is enhanced at
transcriptional levels and/or alternative splicing
steps in the presence of T3.  We also observed
that the induced full-length EGF receptor
mRNA was unstable in the treatment of T3.  It
has been reported that rat mRNAs were
unstable in the presence of a thyroid hormone
than in its absence (Krane et al., 1991; Murphy
et al., 1992).  It has also been explained that the
extension of polyadenylation in the cell nuclei
is downregulated by thyroid hormone (Murphy
et al., 1992; Sachs and Wahle, 1993).
Full-length and truncated EGF receptor
mRNAs were produced by alternative splicing
(Petch et al., 1990).  The expression of trun-
cated EGF receptor mRNA was not affected by
the treatment of T3 (Fig. 1).  The mRNAs have a
common 5' terminal region but truncated
mRNA lacks a 3' terminal region of full-length
form mRNA in rat hepatoma cells (Satoh et al.,
1996).  We hypothesize that the 3' terminal
region of the full-length EGF receptor mRNA
may be involved in the turnover acceleration by
T3 in the rat hepatoma cells.
T3 exerts effects in hepatocellular regener-
ations during cirrhosis and partial hepatectomy
(Knopp et al., 1992; Sasaki et al., 1992; Huang
and Liaw, 1995; Oren et al., 1996).  The experi-
mental findings in the hepatocellular carcinoma
cell line, AH66 may have clinical implications
particularly relevant to liver diseases and
hepatocellular carcinoma.
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Our results suggest that the mode of action
of thyroid hormone mediates the growth-
promoting and developmental effects by the
transient induction of full-length EGF receptor.
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